Evaluation of Immunohistochemical Expression of Beta-catenin and E-cadherin as Epithelial-Mesenchymal Transition Markers in Colorectal Carcinoma - An Analytical Retrospective Study in a Tertiary Care Center
- PMID: 40343243
- PMCID: PMC12058043
- DOI: 10.4103/ijabmr.ijabmr_535_24
Evaluation of Immunohistochemical Expression of Beta-catenin and E-cadherin as Epithelial-Mesenchymal Transition Markers in Colorectal Carcinoma - An Analytical Retrospective Study in a Tertiary Care Center
Abstract
Context: Colorectal carcinoma is a major health concern globally, with varying prognostic outcomes influenced by molecular markers. E-cadherin and beta-catenin are proteins involved in cellular adhesion and signaling pathways, and their aberrant expression has been implicated in tumor progression and metastasis.
Aims: This study aims to evaluate the association between abnormal immunohistochemical expression of E-cadherin and beta-catenin with various clinicopathological parameters in colorectal carcinomas.
Setting and design: A retrospective cross-sectional 3-year analytical study.
Materials and methods: A total of 52 colorectal carcinoma tissue samples were analyzed using immunohistochemistry to assess the expression levels of E-cadherin and beta-catenin. Clinicopathological parameters including age, gender, tumor location, tumor differentiation, depth of invasion, perineural invasion, lymphovascular invasion, and nodal involvement were assessed and correlated with protein expression patterns.
Statistical analysis: SPSS version 24 was used for calculating P values using the Chi-squared test.
Results: Aberrant expression of E-cadherin and beta-catenin was observed in a significant proportion of the tumors. Poorly differentiated tumors showed a marked loss of E-cadherin and abnormal beta-catenin localization. In addition, increased lymphovascular and nodal involvement were significantly associated with these aberrant expression patterns.
Conclusion: The findings suggest that abnormal expression of E-cadherin and beta-catenin is linked to poor tumor differentiation and higher rates of lymphovascular and nodal involvement. These markers may serve as potential biomarkers for assessing prognosis in colorectal carcinoma patients.
Keywords: Beta-catenin; E-cadherin; colorectal carcinoma; immunohistochemistry; prognosis; tumor differentiation.
Copyright: © 2025 International Journal of Applied and Basic Medical Research.
Conflict of interest statement
There are no conflicts of interest.
Figures



Similar articles
-
Combined aberrant expression of E-cadherin and S100A4, but not β-catenin is associated with disease-free survival and overall survival in colorectal cancer patients.Diagn Pathol. 2013 Jun 19;8:99. doi: 10.1186/1746-1596-8-99. Diagn Pathol. 2013. PMID: 23783026 Free PMC article.
-
Association Between the Immunohistochemistry Expression of E-cadherin, Beta-Catenin, and CD44 in Colorectal Adenocarcinoma.Cureus. 2023 Mar 2;15(3):e35686. doi: 10.7759/cureus.35686. eCollection 2023 Mar. Cureus. 2023. PMID: 37012965 Free PMC article.
-
Loss of membrane localization and aberrant nuclear E-cadherin expression correlates with invasion in pancreatic endocrine tumors.Am J Surg Pathol. 2008 Mar;32(3):413-9. doi: 10.1097/PAS.0b013e31813547f8. Am J Surg Pathol. 2008. PMID: 18300809
-
Syndecan-1, Epithelial-Mesenchymal Transition Markers (E-cadherin/β-catenin) and Neoangiogenesis-related Proteins (PCAM-1 and Endoglin) in Colorectal Cancer.Anticancer Res. 2016 May;36(5):2271-80. Anticancer Res. 2016. PMID: 27127133
-
Biomarkers of epithelial-mesenchymal transition: E-cadherin and beta-catenin in malignant transformation of oral lesions.Can J Dent Hyg. 2024 Jun 1;58(2):111-119. eCollection 2024 Jun. Can J Dent Hyg. 2024. PMID: 38974823 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources